Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2016 Aug 19;4(3):28.
doi: 10.3390/dj4030028.

Advantages and Disadvantages of Bone Protective Agents in Metastatic Prostate Cancer: Lessons Learned

Christian Thomas  1 , Georg Bartsch  2 , Christian Walter  3 , Hendrik Borgmann  4 , Maximilian Peter Brandt  5 , Thomas Höfner  6 , Axel Haferkamp  7 , Igor Tsaur  8
Affiliations
Review

Advantages and Disadvantages of Bone Protective Agents in Metastatic Prostate Cancer: Lessons Learned

Christian Thomas et al. Dent J (Basel). .

Abstract

Nine out of ten metastatic prostate cancer (PCa) patients will develop osseous metastases. Of these, every second will suffer from skeletal-related events (SRE). SRE are associated with an increased risk for death, which is markedly increased in the presence of pathological fracture. Moreover, health insurance costs nearly double in the presence of SRE. Zoledronic acid and denosumab are both approved drugs for the prevention or delay of SRE in castration-resistant prostate cancer (CRPC) patients with osseous metastases. However, long-term treatment with one of these two drugs is associated with the development of medication-related osteonecrosis of the jaw (MRONJ). Routine inspections of the oral cavity before and during treatment are mandatory in these patients. Regarding imaging techniques, bone scintigraphy seems to be a promising tool to detect early stage MRONJ. Zoledronic acid does not reduce the incidence of SRE in hormone-sensitive PCa. First data shows 3-monthly application of zoledronic acid to be equi-effective to monthly application.

Keywords: denosumab; osteonecrosis; prostate cancer; zoledronic acid.

PubMed Disclaimer

Conflict of interest statement

The authors declare no conflict of interest.

References

    1. Ryan C.J., Elkin E.P., Small E.J., Duchane J., Carroll P. Reduced incidence of bony metastasis at initial prostate cancer diagnosis: Data from CaPSURE™. Urol. Oncol. 2006;24:396–402. doi: 10.1016/j.urolonc.2005.09.003. - DOI - PubMed
    1. Roehl K.A., Han M., Ramos C.G., Antenor J.A., Catalona W.J. Cancer progression and survival rates following anatomical radical retropubic prostatectomy in 3478 consecutive patients: Long-term results. J. Urol. 2004;172:910–914. doi: 10.1097/01.ju.0000134888.22332.bb. - DOI - PubMed
    1. Moreau J.P., Delavault P., Blumberg J. Luteinizing Hormone-Releasing Hormone Agonists in the Treatment of Prostate Cancer: A Review of Their Discovery, Development and Place in Therapy. Clin. Ther. 2006;28:1485–1508. doi: 10.1016/j.clinthera.2006.10.018. - DOI - PubMed
    1. Heidenreich A., Aus G., Bolla M., Joniau S., Matveev V.B., Schmidt H.P., Zattoni F. EAU guidelines on prostate cancer. Eur. Urol. 2008;53:68–80. doi: 10.1016/j.eururo.2007.09.002. - DOI - PubMed
    1. Beer T.M., Armstrong A.J., Rathkopf D.E., Loriot Y., Sternberg C.N., Higano C.S., Iversen P., Bhattacharya S., Carles J., Chowdhury S., et al. Enzalutamide in metastatic prostate cancer before chemotherapy. N. Engl. J. Med. 2014;371:424–433. doi: 10.1056/NEJMoa1405095. - DOI - PMC - PubMed

LinkOut - more resources